China SXT Pharmaceuticals (2RY3) Stock Statistics & Valuation Metrics
Total Valuation
China SXT Pharmaceuticals has a market cap or net worth of EUR 2.00M. The enterprise value is -EUR 18.25T.
- Market Cap
- EUR 2.00M
- Enterprise Value
- -EUR 18.25T
Share Statistics
China SXT Pharmaceuticals has 686,775 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 686,775
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
China SXT Pharmaceuticals’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -23.11%.
- Return on Equity (ROE)
- -0.21
- Return on Assets (ROA)
- -0.18
- Return on Invested Capital (ROIC)
- -23.11%
- Return on Capital Employed (ROCE)
- -0.23
- Revenue Per Employee
- 19.15K
- Profits Per Employee
- -110.81K
- Employee Count
- 56
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.30
Valuation Ratios
The current PE Ratio of China SXT Pharmaceuticals is -0.00. China SXT Pharmaceuticals’s PEG ratio is 0.00.
- PE Ratio
- -0.00
- PS Ratio
- 0.01
- PB Ratio
- 0.00
- Price to FCF
- -0.00
- Price to Operating Cash Flow
- -0.00
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, China SXT Pharmaceuticals had revenue of 1.07M and earned -6.21M in profits. Earnings per share was -913.00.
- Revenue
- 1.07M
- Gross Profit
- 183.28K
- Operating Income
- -7.12M
- Pretax Income
- -6.07M
- Net Income
- -6.21M
- EBITDA
- -6.98M
- Earnings Per Share (EPS)
- -913.00
Cash Flow
In the last 12 months, operating cash flow was -6.03M and capital expenditures -4, giving a free cash flow of -6.03M billion.
- Operating Cash Flow
- -6.03M
- Free Cash Flow
- -6.03M
- Free Cash Flow per Share
- -1028.71
Dividends & Yields
China SXT Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -40594.06%
- Earnings Yield
- -38102.51%
Stock Price Statistics
- Beta
- -0.06
- 52-Week Price Change
- -100.00%
- 50-Day Moving Average
- 155.82
- 200-Day Moving Average
- 191516.66
- Relative Strength Index (RSI)
- 30.91
- Average Volume (3m)
- 54
Financial Position
China SXT Pharmaceuticals as a current ratio of 7.93, with Debt / Equity ratio of 3.77%
- Current Ratio
- 7.93
- Quick Ratio
- 7.25
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 3.88
- Interest Coverage Ratio
- -113.13
Taxes
In the past 12 months, China SXT Pharmaceuticals has paid 130.84K in taxes.
- Income Tax
- 130.84K
- Effective Tax Rate
- -0.02
Enterprise Valuation
China SXT Pharmaceuticals EV to EBITDA ratio is 3.87, with an EV/FCF ratio of 4.49.
- EV to Sales
- -25.21
- EV to EBITDA
- 3.87
- EV to Free Cash Flow
- 4.49
- EV to Operating Cash Flow
- 4.49
Balance Sheet
China SXT Pharmaceuticals has EUR 28.18M in cash and marketable securities with EUR 1.12M in debt, giving a net cash position of EUR 27.06M billion.
- Cash & Marketable Securities
- EUR 28.18M
- Total Debt
- EUR 1.12M
- Net Cash
- EUR 27.06M
- Net Cash Per Share
- EUR 39.39
- Tangible Book Value Per Share
- EUR 5,070.18
Margins
Gross margin is 17.09%, with operating margin of -996.09%, and net profit margin of -578.49%.
- Gross Margin
- 17.09%
- Operating Margin
- -996.09%
- Pretax Margin
- -566.29%
- Net Profit Margin
- -578.49%
- EBITDA Margin
- -650.71%
- EBIT Margin
- -664.06%
Analyst Forecast
The average price target for China SXT Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -39.44%
- EPS Growth Forecast
- 97.66%
